Kenneth L. Horton
Known title: GC & Corp. Development AdvisorCIK: 0001552047
Associated companies
Transaction History
| SENS | ▼ Sell | Tax Withholding | 9,545 | $69K | 6/15/2026 | View on chart |
| SENS | ▲ Buy | Grant | 157,943 | $0 | 5/19/2026 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 7,320 | $43K | 5/15/2026 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 5,997 | $38K | 11/15/2025 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 35,784 | $18K | 6/16/2025 | View on chart |
| SENS | ▲ Buy | Grant | 505,251 | $0 | 5/23/2025 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 167,085 | $92K | 5/15/2025 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 187,665 | $53K | 11/15/2024 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 80,785 | $32K | 6/15/2024 | View on chart |
| SENS | ▲ Buy | Grant | 1,135,604 | $0 | 5/23/2024 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 108,100 | $54K | 5/15/2024 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 163,319 | $100K | 11/15/2023 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 51,276 | $39K | 6/15/2023 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 137,927 | $102K | 5/15/2023 | View on chart |
| SENS | ▲ Buy | Grant | 782,089 | $0 | 5/15/2023 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 104,306 | $130K | 11/15/2022 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 26,105 | $25K | 6/15/2022 | View on chart |
| SENS | ▲ Buy | Grant | 45,000 | $0 | 5/26/2022 | View on chart |
| SENS | ▲ Buy | Grant | 431,035 | $0 | 5/26/2022 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 45,430 | $51K | 5/16/2022 | View on chart |
| SENS | ▼ Sell | Open Market | 143,126 | $352K | 2/11/2022 | View on chart |
| SENS | ▲ Buy | Grant | 255,287 | $0 | 2/10/2022 | View on chart |
| SENS | ▼ Sell | Tax Withholding | 46,426 | $176K | 11/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Beta Bionics and Senseonics announce iLet-Eversense 365 integration
Beta Bionics and Senseonics announced a deal to integrate the iLet automated insulin delivery system with the Eversense 365 continuous glucose monitor. This partnership aims to provide a more seamless solution for patients managing diabetes. The news highlights a strategic move to combine two major technologies in the diabetes care market.
Beta Bionics and Senseonics announce iLet-Eversense 365 integration. Beta Bionics and Senseonics announced a deal to integrate the iLet automated insulin delivery system with the Eversense 365 continuous glucose monitor. This partnership aims to provide a more seamless solution for patients managing diabetes. The news highlights a strategic move to combine two major technologies in the diabetes care market.